Scholarlink

<p>The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasingly common due to dramatic improvement in clinical outcomes of metabolic conditions. In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma. Then, we summarize clinical data from postmarketting surveillance, randomized controlled trials, and observational studies. Lastly, we present considerations to accurately interpret these data and outline key knowledge gaps for further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Shreyas Krishna,
  • Kathleen M. Dungan,
  • Raj Shah,
  • Zobeida Cruz-Monserrate,
  • Kathleen E. DelGiorno,
  • Marcus Tan,
  • Phil A. Hart

摘要

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasingly common due to dramatic improvement in clinical outcomes of metabolic conditions. In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma. Then, we summarize clinical data from postmarketting surveillance, randomized controlled trials, and observational studies. Lastly, we present considerations to accurately interpret these data and outline key knowledge gaps for further investigation.